Customize your JAMA Network experience by selecting one or more topics from the list below.
Patients who take selective and nonselective serotonin reuptake inhibitors (SRIs) for depression often report treatment-related sexual dysfunction. Selective phosphodiesterase type 5 inhibitors, such as sildenafil, have proven efficacy in the treatment of sexual dysfunction in men, including men with depression, but these agents have received limited study in women. To evaluate the efficacy of sildenafil among women with SRI-associated sexual dysfunction, Nurnberg and colleagues randomly assigned 98 premenopausal women, whose depression was remitted by SRIs but who were experiencing sexual dysfunction since the onset of their depression or antidepressant treatment, to take either sildenafil or placebo before sexual activity. The authors found that compared with those receiving placebo, women who were treated with sildenafil had significant improvement in sexual function during the 8-week trial.
This Week in JAMA . JAMA. 2008;300(4):363. doi:10.1001/jama.300.4.363
Create a personal account or sign in to: